QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 mangorx-gets-patent-notice-of-allowance-in-japan-for-revolutionary-preventive-care-technology

Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, an...

 mangorx-introduces-mojo-pharmaceutical-compounded-formula-featuring-enclomiphene-citrate-and-pregnenolone-for-treatment-of-low-testosterone-and-male-hormone-imbalances--sold-exclusively-on-mangorxs-website-on-a-subscription-basis-at-a-price-of-199-per-month

MOJO to be offered as an Oral Dissolvable Tablet (ODT) marketed to younger male demographic as an alternative to PRIME Testoste...

 mangoceuticals-develops-oral-glp-1s-stock-soars

Mangoceuticals announced the development of proprietary oral formulations of Semaglutide ("Slim") and Tirzepatide ("...

 mangoceuticals-q1-eps-010-up-from-023-yoy-sales-21409k-up-from-10072k-yoy

Mangoceuticals (NASDAQ:MGRX) reported quarterly losses of $(0.10) per share. This is a 56.52 percent increase over losses of $(...

 mangorx-acquires-patent-portfolio-for-total-of-20m-through-issuance-of-980k-of-6-series-c-convertible-preferred-shares

Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, a...

 mangoceuticals-subsidiary-mangorx-mexico-executes-technical-agreement-with-mexican-pharmaceutical-manufacturer-for-initial-development-and-production-of-its-mango-erectile-dysfunction-products

Signifies the first major step towards the application process for the certification of itsMango ED oral dissolvable products b...